Serum levels of oxidative stress marker malondialdehyde in breast cancer patients in relation to pathohistological factors, estrogen receptors, menopausal status, and age

Introduction: The aim of this study was to determine the serum levels of malondialdehyde (MDA) in patients with invasive breast cancer in relation to its serum levels in patients with benign breast disease, and to investigate correlation between MDA serum levels with pathohistological prognostic factors (tumor size, lymph node involvement, and histologic grade [HG]), estrogen receptor (ER) status, and with breast cancer patient’s age and menopausal status. Methods: A total of 43 with well-documented invasive breast cancer were included in this study: 27 with positive axillary’s lymph nodes, and 16 with negative axillary’s lymph nodes, and 39 patients with findings of benign breast diseases. MDA determination in serum of breast cancer and benign breast disease patients was performed by the fluorimetric method, immunohistochemical staining was performed for ER, and routine pathohistological examination was conducted for pathohistological factors. Results: MDA serum levels in breast cancer patients were significantly higher than MDA serum levels in benign breast disease patients (p = 0.042). No statistically significant difference between MDA serum levels in breast cancer patients with and without lymph node metastases was found (p = 0.238). No statistically significant correlations between MDA serum levels and tumor size (p = 0.256), HG (p = 0.124), or number of positive lymph nodes (0.113) were found. A statistically significant correlation between serum MDA levels and ages of breast cancer patients with lymph node metastases was found (p = 0.006). Conclusion: Obtained results support the importance of MDA in the carcinogenesis of breast cancer. According to our findings, serum level of MDA could not be a useful prognostic factor in breast cancer

Antimicrobial and Cytotoxic Activities of Essential Oil from the Aerial Parts of Pulicaria dysenterica (L.) Bernh. (Asteraceae)

The chemical composition of Pulicaria dysenterica (L.) Bernh. aerial parts essential oil (EO), growing wild in Bosnia and Herzegovina, was presented in the study. In addition to the EO composition, antimicrobial and cytotoxic activities were also tested. The aerial parts of P. dysenterica contained 0.3% of yellow, liquid, fragrant EO. The 51 components identified accounted for 81.09% of the oil. The EO was characterized by the presence of a high concentration of oxygenated sesquiterpenes 51.83% while oxygenated monoterpenes constituted 15.57%, sesquiterpene hydrocarbons 9.32% and non-terpene compounds presented 4.37% of the EO. The dominant compounds were the sesquiterpenes caryophyllene oxide, (E)-nerolidol, β-caryophyllene and monoterpene nerol. The antimicrobial activity of EO was tested against selected ATCC strains of microorganisms, the bacteria Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli, and the fungus Candida albicans. The results showed that the investigated EO inhibited the growth of all selected ATCC strains of microorganisms. The best result was obtained against Escherichia coli bacteria with MIC value of 1 mgmL-1. The cytotoxicity of EO was measured against the HeLa cell line using the MTT method with IC50 of 188.52 μgmL-1. This study has provided scientific baseline data on the therapeutic properties of P. dysenterica

Antioxidant and Cytotoxic Activities of Pulicaria dysenterica Methanol Extracts

Aims: The aims of the study were to analyse the polyphenols of Pulicaria dysenterica (L.) Bernh. methanolic extracts from aerial and underground parts, assessment of antioxidant activity and to evaluate their cytotoxicity on HeLa cells of cervical cancer. Methodology: The total phenolic content (TPC) of extracts was determined by the Folin-Ciocalteu spectrophotometric method. The qualitative and quantitative analysis of individual polyphenolic compounds were performed by the reverse phase HPLC method. The antioxidant capacity was evaluated by both, 2,2-diphenyl1-picrylhydrazyl radical and FRAP assay, while cytotoxicity of the extracts was assessed by MTT assay. Results: TPC of the samples were 127.62±2.22 and 244.12±8.84 mg gallic acid equivalent/g extract. In the extracts chlorogenic acid in amount of 10.06±0.96 and 11.32±0.28 mg/g, flavonoid rutin in amount of 5.68±0.13 mg/g and three caffeic acid derivatives were recorded. Extract from underground parts achieved better antioxidant activity with IC50 value 55.36±0.75 µg/mL and FRAP value 2411.12±37.22 µmol Fe2+g-1 compared to the one from aerial parts. Extract from aerial parts achieved better cytotoxic activity with 50% inhibition of viability (IC50) at concentration of 0.389±0.07 mg/mL, against HeLa cells, compared to the extract from underground parts. Conclusion: Analyzed Pulicaria dysenterica extracts contained phenolic acids and flavonoids. The extracts showed good antioxidant activity and cytotoxic properties against HeLa cells in vitro

Comparative study of long-term effects of atorvastatin and rosuvastatin on fasting glucose and hemoglobin A1c in patients with cardiovascular diseases

Introduction: Statins are lipid lowering medications, used for the prevention of cardiovascular diseases (CVD), but have shown to increase the risk of Type 2 diabetes mellitus. The aim of this study was to investigate the effects of high-potency statins, atorvastatin, and rosuvastatin on fasting glucose (FG) and hemoglobin A1c (HbA1c) in CVD patients. Methods: The case–control study included 123 patients from Tuzla Canton, Bosnia, and Herzegovina, with a diagnosis of CVD, treated in three health centers: Public Health Center Gračanica, Banovići, and Čelić. Of total patients, 84 were statin users (39 atorvastatin users and 45 rosuvastatin users) and 39 were not. Demographic data, diagnosis, and data of the therapy were taken from the medical records, as well as data of the FG and HbA1c, measured before or within 3 months of the statin therapy introduction. For the same patients, FG and HbA1c were also measured at least 3 months after the introduction of therapy. Results: Obtained results have shown a significant increase of FG in CVD patients on statin therapy in relation to control (p = 0.034). Comparing the diabetogenic effects of atrovastatin and rosuvastatin, it was found that the HbA1c in patients on atorvastatin therapy was significantly higher comparing to those on rosuvastatain therapy (p = 0.028). The FG was significantly increased (p = 0.027) after atrovastatin therapy. Similar results were obtained in diabetogenic CVD patients, where HbA1c on atorvastatin therapy was significantly higher comparing to HbA1c in those on rosuvastatain therapy (p = 0.039). A significant correlation was found between the increase in FG and HbA1c with the duration of atorvastatin therapy (p = 0.001 and p = 0.033), and between the increase in HbA1c and the duration of rosuvastatin therapy (p = 0.001). Conclusion: Long-term therapy with high-potency statins, atorvastatin, and rosuvastatin, may increase levels of FG and HbA1c in patients with CVD, where atorvastatin shows more significant effects